Pharmacoproteomics and Drug Target Discovery

Pharmacoproteomics, the intersection of pharmacology and proteomics, has a rich history of pioneering efforts to leverage protein profiles for drug target discovery. Early endeavors grappled with the formidable challenge posed by the sheer diversity and abundance of cellular proteins, necessitating the development of sophisticated analytical techniques. Traditional methods like two-dimensional gel electrophoresis (2DIGE) and mass spectrometry (MS) initially struggled to untangle the complexities of biological samples without extensive purification steps, risking the loss of low-abundance proteins crucial for drug targeting. Membrane-bound proteins, such as receptors and ion channels, posed additional hurdles due to their hydrophobic nature and low abundance, further complicating their isolation and identification. Despite these challenges, the field persevered, gradually refining methodologies to enhance sensitivity and specificity. Modern pharmacoproteomics now stands at the forefront of target discovery, buoyed by innovations such as zwitterionic detergents for solubilizing membrane proteins, chemical proteomics for identifying potential drug targets, and integrated chromatography-MS approaches for reducing sample complexity. These advancements underscore pharmacoproteomics’ pivotal role in drug discovery and therapeutic innovation. Particular examples of the application of pharmacoproteomic approaches to understanding neurodegenerative disorders, cardiovascular and infectious diseases, and cancer are considered.